CD8A and neoplasm: A unique property of TIGIT among inhibitory immune checkpoints is that its blockade not only augments anti-tumor effector CD8+ T-cell responses, but also anti-tumor NK-cell responses, and reduces the suppressive capacity of regulatory T cells.